[] Genzyme Corporate [] Genzyme Websites
  • Questions?

  • Make the SYNVISC Connection.
    Call: 1-800-982-8292
    Fax: 1-800-508-8083

  • HCPCS Code J7325
  • HCPCS code per 1 mL.

    Click here for additional code information on Synvisc-One and SYNVISC.

Acquiring Synvisc-One® and SYNVISC®

Specialty Pharmacies

Synvisc-One and SYNVISC (hylan G-F 20) may be obtained at no cost to your practice through a specialty pharmacy for your commercial patients. Specialty pharmacy providers (SPPs) dispense specialty pharmaceuticals and biologics, and offer unique benefits to your patients and your practice, including:

  • Billing and reimbursement support
  • Product inventory and delivery
  • Disease state information and clinical support services for your patients

Using an SPP allows you to focus on patient care by eliminating the financial risk that carrying inventory for your commercial patients can pose.

View Speciality Pharmacy Forms

Buy and Bill

With Buy and bill your office purchases Synvisc-One or SYNVISC directly through Genzyme then collects appropriate patient co-pays for Synvisc-One/SYNVISC and the office visit. Your office bills the health plan for the cost of the drug and associated administration costs.

Indication

SYNVISC® (hylan G-F 20) and Synvisc-One® (hylan G-F 20) are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information

SYNVISC and Synvisc-One are contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the target knee. Use caution when injecting SYNVISC or Synvisc-One in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee to be treated.

Patients should be advised to avoid strenuous or prolonged weight-bearing activities for approximately 48 hours after treatment. Aspiration of any effusion prior to injection is highly recommended. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC and Synvisc-One have not been established in children or in pregnant or lactating women. It is unknown whether SYNVISC or Synvisc-One is excreted in human milk.

For SYNVISC
In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

View the Complete Prescribing Information for SYNVISC (PDF)

For Synvisc-One
The most commonly reported related local adverse events were transient, mild-to-moderate arthralgia, arthritis, arthropathy, injection site pain and joint effusion. No serious adverse events were reported in clinical trials in knees injected with Synvisc-One. Serious local adverse events have been reported only rarely in post-marketing use.  Repeat treatment did not affect the safety profile. In the pivotal clinical trial, there was one related systemic event of syncope. The most common systemic side effects irrespective of relationship to Synvisc-One were headache, back pain, nasopharyngitis and influenza. Systemic adverse event profiles were similar between patients in the Synvisc-One and Saline Control groups.

View the Complete Prescribing Information for Synvisc-One (PDF)